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Abstract 
A simple stability indicating reversed-phase HPLC method was developed and 
subsequently validated for estimation of Cefpirome sulphate (CPS) present in 
pharmaceutical dosage forms. The proposed RP-HPLC method utilizes a 
LiChroCART-Lichrosphere100, C18 RP column (250 mm × 4mm × 5 µm) in an 
isocratic separation mode with mobile phase consisting of methanol and water 
in the proportion of 50:50 % (v/v), at a flow rate 1ml/min, and the effluent was 
monitored at 270 nm. The retention time of CPS was 2.733 min and its 
formulation was exposed to acidic, alkaline, photolytic, thermal and oxidative 
stress conditions, and the stressed samples were analyzed by the proposed 
method. The described method was linear over a range of 0.5–200µg/ml. The 
percentage recovery was 99.46. F-test and t-test at 95% confidence level were 
used to check the intermediate precision data obtained under different 
experimental setups; the calculated value was found to be less than the critical 
value. 
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Introduction 
Cefpirome is chemically (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)-
acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-aza-
bicyclo[4.2.0]oct-2-ene-2-carboxylate (Figure 1). It is a  broad-spectrum semisynthetic 900  K. Srinivasa Rao, K. N. Kumar, and D. Joydeep:   
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β-lactamase resistant fourth generation cephalosporin bearing a quaternary ammonium 
group at the 3 position of the cephem nucleus. It is used for the treatment of upper and 
lower urinary tract  as well aslower  respiratory tract, skin and soft tissue infections. 
Cefpirome is excreted largely unchanged in the urine with a half-life of 2 hours [1]. It has 
an expanded spectrum of activity against  Pseudomonas sp., enterococci, and 
staphylococci, as well as other gram-positive and gram-negative bacteria [2]. 
N
S
O
N
H
O
-
O
N
+
O
N
N
O
S
NH2
H H
S
O
O
OH O H
 
Fig. 1.  Cefpirome Sulphate 
Forced degradation or stress testing is undertaken to demonstrate specificity when 
developing stability-indicating methods, particularly when little information is available 
about potential degradation products. The ICH guideline entitled “Stability Testing of New 
Drug Substances and Products” requires the stress testing to be carried out to elucidate 
the inherent stability characteristics of the active substances. The purpose of stability 
testing is to provide evidence on how the quality of a drug substance or drug product 
varies with time under the influence of a variety of environmental factors such as 
temperature, humidity, and light; it enables recommendation of storage conditions, retest 
periods, and shelf lives to be established. Regulatory agencies recommend the use of 
stability-indicating methods for the analysis of stability samples. Thus, stress studies are 
required in order to generate the stressed samples, method development and method 
validation [3]. Forced degradation of CPS was performed under stress conditions (acid, 
alkaline, photolytic, thermal and oxidative), to establish the stability indicating nature of the 
method, and stressed samples were analyzed by the proposed method. The proposed RP-
HPLC method was validated by assessing its specificity, linearity, accuracy, precision, 
limits of detection and quantification, system suitability parameters, ruggedness and 
robustness. 
Many  researchers  reported methods for the assay of cefpirome  in pharmaceutical 
formulations and in human serum [4–9]. These methods involve either complicated mobile 
phases or buffers that may be corrosive to the column or flow system of HPLC. Previous 
investigators [10–13] have also involved various microbiological assay methods, including 
both microdilution and agar dilution, to quantitate cefpirome. Two studies [13, 14] reported 
the pharmacokinetics of cefpirome in adults after quantitation of the compound in serum by 
using high-performance liquid chromatography (HPLC) assay for which specific details 
were not provided.  
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Experimental 
Chemicals and Reagents 
Gift sample of CPS was received from Alkem Labalories, Mumbai, India. HPLC grade 
methanol was purchased from Rankem, India. Hydrogen peroxide was purchased from 
Qualigens Fine chemicals, India and sodium hydroxide was purchased from Merck Ltd. 
India. High pure water was prepared by using Millipore Milli Q plus puriﬁcation system. 
Commercial formulations Bacirom® (vial) and Forgen® (vial) containing 250mg of CPS 
were purchased from the local market.  
HPLC instrumentation and conditions 
Quantitative HPLC was performed on Shimadzu HPLC with LC 10 AT VP series pumps 
besides SPD 10 A VP UV-Visible detector. The chromatographic separations  were 
performed using LiChroCART-Lichrosphere100, C18, RP column (250 mm × 4mm × 5 µm) 
maintained at ambient temperature, eluted with mobile phase at a flow rate of 1ml/min for 
10 min. The mobile phase consisted of methanol-water (50:50 % v/v). Measurements were 
made with injection volume 20µl and ultraviolet (UV) detection at 270 nm. 
Standard and Sample Preparation 
The standard stock solution of CPS (1mg/ml) was prepared by dissolving 25 mg CPS in 25 
ml volumetric flask containing 10 ml of methanol and 10 ml of water. The solutions was 
sonicated for about 10 min and later  diluted  to desired volume with mobile phase. 
Standard calibration solutions of CPS having concentration in the range of 0.5–200µg/ml 
were prepared by diluting stock solution with mobile phase. 
From the vial equivalent to 25 mg of CPS content was transferred into a 25ml volumetric 
flask containing 15 ml mixture of methanol and water, ultrasonicated for 15 min, and then 
diluted up to the mark with mobile phase to yield sample stock solution. A small portion of 
sample solution was filtered through 0.45µm filter paper and used for injection on HPLC. 
Procedure for forced degradation study 
Forced degradation of each drug substance and the drug product was carried out under 
acid, alkaline, photolytic, thermal and oxidative stress conditions. Acid degradation of drug 
substance and drug product in solution state was conducted with 0.1N hydrochloric acid 
for 48 h. Before injecting to HPLC system the samples were neutralized with 0.1N sodium 
hydroxide solution and made up to volume with mobile phase. Alkaline degradation of drug 
substance and drug product in solution state was conducted with 0.1N sodium hydroxide 
for 48 h.  Before injecting to HPLC system the samples were neutralized with 0.1N 
hydrochloric acid solution and made up to volume with mobile phase. For photolytic stress, 
sample solutiosn of drug substance and drug product, were kept for 24 h in direct sunlight. 
For thermal degradation study, the sample solutions were kept in water bath for 2 h at 
80°C, and after exposure to heat it was cooled to room temperature. For oxidative stress, 
sample solutions of drug substance and drug product of CPS, in 3% hydrogen peroxide 
were kept at ambient temperature for 48 h. Before injecting to HPLC system the samples 
were made up to volume with mobile phase. From these solutions, 20 µl were injected 
separately in HPLC system to obtain chromatograms.  902  K. Srinivasa Rao, K. N. Kumar, and D. Joydeep:   
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Results and Discussion 
Optimization of the Method 
The proposed RP-HPLC method utilizes a LiChroCART-Lichrosphere100, C18 RP column 
(250 mm × 4mm × 5 µm) in an isocratic separation mode with mobile phase methanol and 
water in the proportion of 50:50 % (v/v), at a flow rate 1ml/min and the effluent was 
monitored at 270 nm. The retention time of CPS was 2.733 min. Degradation products 
resulting from the stress studies did not interfere with the detection of CPS, and the assay 
is thus stability-indicating.  
Results of forced degradation studies 
Much degradation was observed in CPS samples under all stress conditions such as acid 
(fig. 2a and 2b), alkaline hydrolysis (fig. 2c and 2d), oxidative (fig. 2e and 2f), photolysis 
(fig. 2g and 2h) and thermal degradation (fig. 2i and 2j). Table 1 indicates the extent of 
degradation of CPS under various stress conditions. Drug degradation was observed 
when CPS was treated with mild alkali (in 0.1N NaOH for 48 h.) and a new degradant was 
eluted at 1.6 min. When exposed to direct sun light for 24 h. its degradants show different 
peaks at 1.2 min, 4.383 min, which indicate that CPS is sensitive to light. Under oxidation, 
one major degradant and some unknown degradation products were formed (Fig. 2e and 
2f). The pure as well as formulation were showing total degradation under oxidative stress 
testing. When CPS was treating with 80°C of temperature for 2 h it was degrade and some 
new peaks were formed. Assay of CPS was unaffected by the presence of other 
degradants which confirms the stability-indicating power of the method.  
Tab. 1.  Results of analysis of forced degradation study 
Stress condition/duration  CPS 
  % Recovery  Retention Time 
Acid degradation 
RS (0.1N HCL/48 h) 
Formulation (0.1N HCl/48 h) 
 
84.352 
81.903 
 
2.683 
2.658 
Alkaline degradation 
RS (0.1N NaOH/ 48 h) 
Formulation (0.1N NaOH/ 48 h) 
 
70.717 
73.562 
 
1.617 
1.608 
Photolysis 
RS (Sun light/24 h) 
Formulation (Sun light/24 h) 
 
87.403 
70.925 
 
2.717 
2.725 
Thermal degradation 
RS (water bath/2 h at 80°C) 
Formulation (water bath/2 h at 80°C) 
53.350 
52.229 
1.317 
1.308 
Oxidative degradation 
RS (3%w/v /48 h) 
Formulation (3%w/v /48 h) 
 
96.982 
87.791 
 
2.100 
2.067 
RS…reference standard. 
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Fig. 2.  Representative chromatogram 
a) Pure CPS (10µg/ml) in acidic SC   b) CPS (formulation) in acidic SC 
c) Pure CPS (10µg/ml) in alkaline SC  d) CPS (formulation) in alkaline SC 
e) Pure CPS (10µg/ml) in oxidative SC  f) CPS (formulation) in oxidative SC 
g) Pure CPS (10µg/ml) in photolytic SC  h) CPS (formulation) in photolytic SC 
i) Pure CPS (10µg/ml) in thermal SC  j) CPS (formulation) in thermal SC 
k) A Typical Chromatogram of CPS (10µg/ml) in pure form 
l) A Typical Chromatogram of CPS (10µg/ml) in Formulation 
SC…stress condition 904  K. Srinivasa Rao, K. N. Kumar, and D. Joydeep:   
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Method validation 
The described method has been validated for linearity, precision, accuracy, specificity, 
LOD and LOQ, system suitability parameters, ruggedness and robustness.  
Linearity 
Least square regression analysis was carried out for the slope, intercept and correlation 
coefficient (Table 2). The linear fit of the system was illustrated graphically. The linearity 
range was found to be 0.5–200µg/ml. Regression equation for CPS was  
y = 24341x + 4144.8 (R
2 = 0.9999) 
Tab. 2.  Regression characteristics of the proposed HPLC method 
Linearity experiment 
(n=5)  CPS 
Range (µg/ml)  0.5–200 
Mean ‘R’ value  0.9995 
Slope  24341 
Intercept  4144.8 
 
Accuracy 
This experiment was performed at three levels in which sample stock solutions were 
spiked with standard drug solution containing 80, 100 and 120% of labeled amount of the 
drugs (250 mg CPS) in vial. Three replicate samples of each concentration level were 
prepared and the % recovery at each level (n = 3), and mean % recovery (n=9) were 
determined (Table 3). The mean recovery was 99.46 %. 
Tab. 3.  Results of Accuracy experiment using proposed method 
  CPS 
  Taken(µg)  Recovered (µg)  % Recovery 
LEVEL 1(80)  8  7.96  99.53 
LEVEL 2(100)  10  9.96  99.64 
LEVEL 3(120)  12  11.90  99.23 
Mean % recovery (n=9)    99.466±0.254   
%RSD    0.253   
 
Precision 
The precision of the proposed method was evaluated by carrying out eight independent 
(50µg/ml) assays of test sample. RSD (%) of eight assay values obtained was calculated. 
Intermediate precision was carried out by analyzing the samples by a different analyst on 
another  instrument.  F-test and t-test  were  applied to the two sets of  data at 95% 
confidence  level, and no statistically significant difference was observed. The resultant 
data was presented in table 4.   New Stability Indicating RP-HPLC Method for the Estimation of Cefpirome Sulphate in Bulk …  905 
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Tab. 4.  Results of Precision study 
Precision  CPS 
  Mean assay (%)/%R.S.D 
Set 1(n=5) 
Set 2(n=5) 
99.8/0.929 
99.6/0.871 
  Calculated value/ critical value 
F-test 
t-test 
0.920/3.368 
0.427/2.106 
 
Specificity 
Specificity is the ability to measure accurately and specifically the analyte of interest in the 
presence of other components that may be expected to be present in the sample matrix. It 
was found that the proposed method was specific because there is no interference of other 
active ingredients and excipients, ensuring that the peak response is due only to a single 
component. Based on the results, obtained from the analysis of forced degraded samples 
using the described method, it can be concluded that the method is specific for estimation 
of CPS in presence of degradants. 
LOD and LOQ  
The detection and quantification limits were evaluated from calibration curves plotted in 
concentration range  of  0.5–200µg/ml. The acceptance criterion for these replicate 
injections was RSD not more than 30% for LOD concentration and not more than 10% for 
LOQ concentration. The formulae used were LOD= 3.3σ/S and LOQ= 10σ/S (where σ = 
standard deviation of response and S = slope of calibration curve). The standard drug 
solutions for each value of LOD and LOQ concentration were injected 5 times. % RSD 
values for the area of replicate injections were calculated. LOD and LOQ for this method 
were found to be 0.110 and 0.364, respectively. These values indicated the method was 
very sensitive to quantify the drug. 
System suitability parameters 
System suitability parameters can be defined as tests to ensure the method can generate 
results of acceptable accuracy and precision. The system suitability parameters like 
Theoretical plates (N), Resolution (R), and  Tailing factor (T) were calculated and 
compared with the standard values to ascertain whether the proposed RP-HPLC method 
for the estimation of CPS in pharmaceutical formulations was validated or not. System 
suitability is usually developed after method development and validation has been 
completed. The obtained value of Theoretical plates (N) in this method was 4369, and the 
tailing factor was found to be 1.224. 
Robustness 
The percentage recovery of CPS was good under most conditions and did not show any 
significant change when the critical parameters were modified. The tailing factor was 
always less than 2.0, and the components were well separated under all the changes 
carried out. Thus the method conditions were robust.  906  K. Srinivasa Rao, K. N. Kumar, and D. Joydeep:   
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Assay 
The validated method was applied to the determination of CPS in commercially available 
Bacirom®  (vial) and Forgen®  (vial).  Figure 2k-2l  illustrates two typical HPLC 
chromatograms obtained from CPS standard solution and from the assay of Bacirom®. 
The observed concentration of CPS  was  found to be 247.67±0.271mg  (mean±SD)  for 
Bacirom® and 247.95±0.08 for Forgen®. The results of the assay (n  = 9) undertaken 
yielded 99.06 % (%RSD = 0.1) of label claim for CPS in Bacirom® and 99.18 % (%RSD = 
0.032) of label claim for CPS in Forgen®. The retention times of CPS were found to be 
2.733 and 2.758 for standard drug and formulation, respectively. The results of the assay 
indicate that the method is selective for the estimation of CPS without interference from 
the excipients used to formulate and produce these tablets. 
Conclusion 
The LC method described here is a very simple, sensitive, and accurate procedure for 
estimation of CPS. The developed and validated LC method is stability-indicating  and 
enables specific, accurate, robust and precise analysis of CPS  in formulations.  The 
method  is sensitive enough for quantitative detection of  the analyte in pharmaceutical 
preparations. The proposed method can thus be used for routine analysis, quality control 
and for  studies of the stability of pharmaceutical tablets containing these  drugs. The 
validation data indicate good precision, accuracy and reliability of the method. The sample 
recoveries in all formulations were in agreement with their respective label claims, and 
they suggested non-interference of formulation excipients in the estimation.  
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